RELMADA THERAPEUTICS, INC. Retained Earnings, Appropriated
RELMADA THERAPEUTICS, INC. (RLMD) had Retained Earnings, Appropriated of $560.90 million as of 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAppropriated · last filed 2024-03-19
- 2023-12-31: Retained Earnings, Appropriated $560.90M.
- 2023-06-30: Retained Earnings, Appropriated $513.74M.
- 2023-03-31: Retained Earnings, Appropriated $488.43M.
- 2022-12-31: Retained Earnings, Appropriated $462.11M.
| Period end | Retained Earnings, Appropriated |
|---|---|
| 2023-12-31 | $560.90M 10-K · filed 2024-03-19 |
| 2023-06-30 | $513.74M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $488.43M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $462.11M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |